Clinical Trials Directory

Trials / Completed

CompletedNCT00285298

Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients

Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Walter Reed Army Medical Center · Federal
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the investigators study is to assess the impact of therapy with Pentoxifylline (PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk for progression to end-stage renal disease. The investigators hypothesize that therapy with Pentoxifylline will slow progression of kidney disease over time.

Detailed description

The treatment objective for chronic kidney disease (CKD), regardless of etiology, is to slow or halt progression of renal dysfunction and reduce proteinuria (in those patients with proteinuric renal disease). Multi-drug medical regimens remain the cornerstone of therapy for medical-renal disease, often with an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker. These therapies, though often efficacious, have not been shown to halt disease progression entirely, and the medical therapy of renal disease remains suboptimal. PTF is a safe, generally well-tolerated drug currently indicated for symptomatic and functional relief of intermittent claudication presumed due to chronic occlusive arterial disease of the limbs. A number of small studies in patients across a range of renal disease states show that PTF can reduce proteinuria, an important component of treatment of CKD. It is not known, however, if the drug will slow progression of CKD as measured by glomerular filtration rate. Comparisons: subjects randomized to receive PTF compared with those randomized to receive placebo

Conditions

Interventions

TypeNameDescription
DRUGPentoxifylline
DRUGPlacebo

Timeline

Start date
2006-01-01
Primary completion
2008-04-01
Completion
2008-04-01
First posted
2006-02-01
Last updated
2011-07-29

Source: ClinicalTrials.gov record NCT00285298. Inclusion in this directory is not an endorsement.